Novo Nordisk expects a decline in sales of up to 13 per cent this year as the Danish drugmaker competes in an increasingly crowded obesity-treatment market and faces pressure on the pricing of its drugs.
The company delivered the warning as it announced net sales of DKr309bn ($48.9bn) in 2025, a 10 per cent increase against the previous year at constant exchange rates, buoyed by growth in the US and its international operations.
The company reported sales of its popular obesity and diabetes treatments had risen 10 per cent to DKr289.5bn, driven largely by a rise in obesity care sales.
您已阅读17%（589字），剩余83%（2922字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。